Reuters logo
8 months ago
BRIEF-Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer
December 21, 2016 / 10:05 PM / 8 months ago

BRIEF-Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer

Dec 21 (Reuters) - Prima BioMed Ltd :

* Prima BioMed Ltd - data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells

* Prima BioMed Ltd - IMP321 is safe and well tolerated

* Prima BioMed Ltd - subject to confirmation of dose escalation committee on 30 Dec, Prima will now commence randomised phase of trial in January 2017

* Prima BioMed Ltd - patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with imp321

* Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below